June 19, 2013 — Magnetic resonance imaging (MRI) scans of children who have had chemotherapy can detect early changes in their hearts finds research in the Journal of Cardiovascular Magnetic Resonance.

Chemotherapy with anthracyclines, such as doxorubicin, is one of the most effective treatments against many types of cancer, including leukaemia and Hodgkin's lymphoma, breast, lung and ovarian cancer. However it can also lead to irreversible heart damage, which may not be apparent until several years after treatment. Being able to detect this damage at an early stage in order to initiate preventative therapy of affected people is especially important in children.

Researchers from University of Alberta performed MRI scans on children and young adults (aged 7 to 19) at the Stollery Children's Hospital who were in remission following anthracycline treatment. They found that they were able to identify changes in heart muscle related to the formation of fibrosis, using an emerging MRI method called T1 mapping, even in children whose heart function was apparently normal by ultrasound.

Explaining in more detail, the study funded by the Women's and Children's Health Research Institute led by Dr. Edythe Tham and Dr. Richard Thompson said, "In childhood cancer survivors, MRI changes were related to anthracycline dose given to the children. These changes are also mirrored by thinning of the heart wall and a reduction in the exercise capacity. By detecting these changes early we can only hope that future research using these techniques may guide early identification and treatment in attempts to delay the onset of heart damage in children who have survived cancer."


Related Content

News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
News | Women's Health

Aug. 19, 2024 — GE HealthCare recently announced a collaboration with the University of California San Diego School of ...

Time August 29, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
Subscribe Now